RE:RE:I am still holding onto my shares.I would be surprised if the stock price recovered much any tme soon. I think investors are dusturbed with this CRL. Based on Ken's statements over the last few months, he pretty much all but guaranteed an approval with an expanded label. He went on and on how the dialogue with the FDA was very good and they fully expected approval by the PDUFA date. Confidence in Ken has taken a big hit, imo. Couple this with declining revenues (compare last quarter with the previous quarter) and you have a company that is not executing well at all right now. The stock price hit, which has continued today, is justified imo. It is disappointing the ceo couldn't hold some sort of conference going over what may have happened. They spent a lot of money to get this drug and now with potentially a substantial delay, costs associated to possibly run new trials, this is a bad situation. If they do not report strong numbers at the next earnings call, you could see another hit. And given how biotech has been hammered for quite a while, even if they eventually get approval, who knows if the stock will rebound. Investors may not even care they got approval or they will wait for confirmation the drug sells which will take more time. Deciding not to join the nasdaq suddendly after Ken cointunued to mention it would happen is another expample of why some may question the credibility of the ceo. Although some argue it's better they don't join the nasdaq for some reason (i don't agree as this company has no following on these exchanges), why was Ken mentioning it over and over and then suddenly, without elaboration, cancel the process?